Featured Articles

Gilead Sciences, Inc. announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for…
Read More...

Mallinckrodt plc announced that the U.S. Food and Drug Administration (FDA) approved Terlivaz (terlipressin) for injection. Terlivaz is the first and only FDA-approved product indicated…
Read More...

Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the…
Read More...

Pfizer Inc. announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug…
Read More...

Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per…
Read More...

Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off. The spin-off aims…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung…
Read More...

Gilead Sciences, Inc. and MiroBio announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in…
Read More...

Pfizer Inc., MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate…
Read More...

GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston,…
Read More...

Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price…
Read More...

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO …
Read More...

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of…
Read More...

Novartis announced that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Read More...

Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced an expansion of…
Read More...

Pfizer Inc. and BioNTech SE announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the…
Read More...

Astellas Pharma Inc. and Seagen Inc. announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally…
Read More...

UCB announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine…
Read More...

Novartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids…
Read More...